FacebookTwitterGoogle+RedditEmail

Health Care and the TPP

by

The latest release from WikiLeaks on parts of the Trans-Pacific Partnership Agreement dealing with medical insurance and medical systems goes some way in affirming the destructive potential the agreement has.[1] Forged in the corridors of unaccountable secrecy, officials have been undermining their own sovereign systems at stages, even as they claim it to be in their country’s interest.

The draft chapters released by WikiLeaks have already revealed the extent corporations will be privileged with an assortment of investment protections, while broader environmental protections will be undermined. The entire agreement reads like a catastrophic abdication of sovereignty and state responsibility. The boardroom triumphs over the parliamentary chamber.

In an analysis of the Annex on transparency and procedural fairness for pharmaceutical products by Jane Kelsey of the Law Faculty at Auckland University, we are told that the document “seeks to erode the processes and decisions of agencies that decide which medicines and medical devices to subsidise with public money and by how much.”[2]

Provinces where the state should stand guard will be subject to a shadow occupation. The TPP acts as an ultimate ground clearance, a form of scorched earth policy on traditional protections. One such area is that of state-run medical schemes. Investor-state disputes have the potential of cutting deep there, where the investors (corporations, for the most part) will have a legitimate expectation to be treated fairly and equitably. This may arise in cases where subsiding medicines or medical devices could be challenged as negatively affecting investments.

For that reason, Australia, in the leaked investment chapter of January 2015, specified that its own Pharmaceutical Benefits Scheme, Medicare Benefits Scheme, and Therapeutic Goods Administration and Office of the Gene Technology Regulation would be exempt from such investor state dispute settlement.

The analysis on the potential effect of the agreement on New Zealand’s Pharmaceutical Management Agency (Pharmac) is telling. It also reveals the persistent doublespeak of diplomats who are proclaiming one reality for citizens, and another for the strategic, US-led fold.

US Trade officials and members of the pharmaceutical industry have made it clear that Pharmac is the bogey to their vision of free trade. Established in 1993, its aim was “to secure for eligible people in need of pharmaceuticals the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided” (Disability Act 2000, s. 47).

Its role is singular and expansive, covering the negotiation of prices of medical products with the pharmaceutical companies and levels of reimbursement. It is also a dream for those concerned about skyrocketing costs in the medical sector. The US pharmaceutical industry has expressed a different view, seeing it as the grand obstacle, “an egregious example” of a model that pushes down prices of medicines and medical devices at the expense of profit.

The submission to the US government by the industry in 2011 regarding the TPPA specifically made that point, further noting the sanctity of intellectual property, which was being violated by this perceived lack of transparency. The powerful were feeling slighted.

The US annual report on Special 301 (2015) by Michael Froman, covering intellectual property issues, notes “serious concern about the policies and operation of New Zealand’s Pharmaceutical Management Agency (PHARMAC), including, among other things, the lack of transparency, fairness and predictability of the PHARMAC pricing and reimbursement scheme, as well as the negative aspects of the overall climate for innovative medicines in New Zealand.”

The discussion about fairness and transparency has little to do with accrued benefits for citizens. The trade scheme on the table has everything to do with the corporate wallet and its anticipated depth. Fair treatment towards citizens, which would entail keeping medical costs down and make health care accessible, is less significant than pharmaceutical profit margins. But just to remind us about how the US negotiating position on this has been shaped, we need only see that it deems its own state run schemes to be exempt from the free trade bonanza.

The schemes of other countries are to be targeted, while domestic interests are satisfied. This strategy was exactly the same one pursued in making the free trade agreement with Australia. “USTR has worked closely with all relevant US agencies to ensure the FTA does not require any changes to US health care programs.” The US trade lobby pilfers, while the smaller state run schemes suffer.

There are signs that the free trade ideology may not be receiving the same purchase on the Hill it once did. Last Friday, the House of Representatives voted down the Trade Promotion Authority to “fast track” the TPPA negotiations.[3] While this is far from suggesting that the members have gone cold on regional trade agreements, it suggests that providing the executive vast powers to push supposedly “free” trade deals is a source of concern. Greater scrutiny is required.

Outside the various parliaments involved, resistance to the TPPA has reinvigorated the anti-globalisation movement, finding form in a grass roots resistance that is gradually breaking through the manufactured consensus on free trade. Free trade is the age’s great oxymoron, and deserves banishment from the lexicon of political engagement.

Dr. Binoy Kampmark was a Commonwealth Scholar at Selwyn College, Cambridge. He lectures at RMIT University, Melbourne. Email: bkampmark@gmail.com

Notes. 

[1] https://wikileaks.org/tpp/healthcare/

[2] https://wikileaks.org/tpp/healthcare/Professor-Jane-Kelsey-Analysis-on-TPP-Transparency-for-Healthcare-Annex.pdf

[3] http://www.abc.net.au/news/2015-06-16/berg-tpp-not-the-bogey-treaty-that-we-think-it-is/6547242

Binoy Kampmark was a Commonwealth Scholar at Selwyn College, Cambridge. He lectures at RMIT University, Melbourne. Email: bkampmark@gmail.com

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
May 26, 2017
Friday - Sunday
Anthony DiMaggio
Swamp Politics, Trump Style: “Russiagate” Diverts From the Real White House Scandals
Paul Street
It’s Not Gonna Be Okay: the Nauseating Nothingness of Neoliberal Capitalist and Professional Class Politics
Jeffrey St. Clair
The ICEmen Cometh
Ron Jacobs
The Deep State is the State
Pete Dolack
Why Pence Might be Even Worse Than Trump
Patrick Cockburn
We Know What Inspired the Manchester Attack, We Just Won’t Admit It
Thomas Powell
The Dirty Secret of the Korean War
Mark Ashwill
The Fat Lady Finally Sings: Bob Kerrey Quietly Resigns from Fulbright University Vietnam Leadership Position
John Davis
Beyond Hope
Uri Avnery
The Visitation: Trump in Israel
Ralph Nader
The Left/Right Challenge to the Failed “War on Drugs”
Traci Yoder
Free Speech on Campus: a Critical Analysis
Dave Lindorff
Beware the Supporter Scorned: Upstate New York Trump Voters Hit Hard in President’s Proposed 2018 Budget
Daniel Read
“Sickening Cowardice”: Now More Than Ever, Britain’s Theresa May Must be Held to Account on the Plight of Yemen’s Children
Ana Portnoy
Before the Gates: Puerto Rico’s First Bankruptcy Trial
M. Reza Behnam
Rethinking Iran’s Terrorism Designation
Brian Cloughley
Ukraine and the NATO Military Alliance
Josh Hoxie
Pain as a Policy Choice
David Macaray
Stephen Hawking Needs to Keep His Mouth Shut
Ramzy Baroud
Fear as an Obstacle to Peace: Why Are Israelis So Afraid?
Kathleen Wallace
The Bilious Incongruity of Trump’s Toilet
Seth Sandronsky
Temping Now
Alan Barber – Dean Baker
Blue Collar Blues: Manufacturing Falls in Indiana, Ohio and Pennsylvania in April
Jill Richardson
Saving America’s Great Places
Richard Lawless
Are Credit Rating Agencies America’s Secret Fifth Column?
Louis Proyect
Venezuela Reconsidered
Murray Dobbin
The NDP’s Singh and Ashton: Flash Versus Vision
Ron Leighton
Endarkenment: Postmodernism, Identity Politics, and the Attack on Free Speech
Anthony Papa
Drug War Victim: Oklahoma’s Larry Yarbrough to be Freed after 23 Years in Prison
Rev. John Dear
A Call to Mobilize the Nation Over the Next 18 Months
Yves Engler
Why Anti-Zionism and Anti-Jewish Prejudice Have to Do With Each Other
Ish Mishra
Political Underworld and Adventure Journalism
Binoy Kampmark
Roger Moore in Bondage
Rob Seimetz
Measuring Manhoods
Edward Curtin
Sorry, You’re Not Invited
Vern Loomis
Winning the Lottery is a State of Mind
Charles R. Larson
Review: Mary V. Dearborn’s “Ernest Hemingway”
David Yearsley
The Ethos of Mayfest
May 25, 2017
Jennifer Matsui
The Rise of the Alt-Center
Michael Hudson
Another Housing Bubble?
Robert Fisk
Trump Meets the New Leader of the Secular World, Pope Francis
John Laforge
Draft Treaty Banning Nuclear Weapons Unveiled
Benjamin Dangl
Trump’s Budget Expands War on the Backs of America’s Poor
Alice Donovan
US-Led Air Strikes Killed Record Number of Civilians in Syria
Andrew Moss
The Meaning of Trump’s Wall
FacebookTwitterGoogle+RedditEmail